Nanopore-based targeted sequencing test for direct tuberculosis identification, genotyping, and detection of drug resistance mutations: a side-by-side comparison of targeted next-generation sequencing technologies.
Andrea Maurizio CabibbeKiarash MoghaddasiVirginia BatignaniGodstime Stephen Kojo MorganFederico Di MarcoDaniela Maria CirilloPublished in: Journal of clinical microbiology (2024)
provides comprehensive resistance predictions matched to new multidrug-resistant/rifampicin-resistant tuberculosis regimens and received World Health Organization approval for clinical use in respiratory samples in 2024. The advanced version of the Oxford Nanopore Diagnostics AmPORE TB tNGS kit was evaluated in this study for the first time and demonstrated good performance, flexibility, and faster turnaround time compared with the existing solutions.
Keyphrases
- mycobacterium tuberculosis
- multidrug resistant
- pulmonary tuberculosis
- single molecule
- cancer therapy
- hiv aids
- drug resistant
- high throughput
- emergency department
- acinetobacter baumannii
- copy number
- gram negative
- gene expression
- escherichia coli
- real time pcr
- circulating tumor
- quantum dots
- cell free
- drug administration